Blood vessel cells express the 2 known estrogen receptors, ␣ and ␤ (ER␣, ER␤), which are thought to mediate estrogen inhibition of vascular injury and atherosclerosis, but the relative role of ER␣ and ER␤ in these events is controversial. Estrogen inhibits the vascular injury response to the same extent in ovariectomized female wild-type mice and in the original single gene knockout mice for ER␣ (ER␣KO Chapel Hill [ER␣KO CH ]) and ER␤ (ER␤KO Chapel Hill [ER␤KO CH ]). In double gene knockout mice generated by crossing these animals (ER␣,␤KO CH ), estrogen no longer inhibits medial thickening after vascular injury, but still inhibits vascular smooth muscle cell proliferation and increases uterine weight. The partial retention of estrogen responsiveness in ER␣,␤KO CH mice could be due either to the presence of a novel, unidentified estrogen receptor or to functional expression of an estrogen receptor-␣ splice variant in the parental ER␣KO CH mice. To distinguish between these possibilities, we studied recently generated mice fully null for estrogen receptor ␣ (ER␣KO Strasbourg [ER␣KO St ]) and examined the effect of estrogen on the response to vascular injury. In the present study, we show that after vascular injury in ovariectomized ER␣KO St mice, estrogen has no detectable effect on any measure of vascular injury, including medial area, proteoglycan deposition, or smooth muscle cell proliferation. These data demonstrate that estrogen receptor-␣ mediates the protective effects of estrogen on the response to vascular injury. (Circ Res. 2002;90:1087-1092.) 
T he cardiovascular effects of steroid hormones are an area of intense interest at present. Estrogen has known systemic effects on circulating factors and has more recently been established to have direct effects on the blood vessel wall. Estrogen causes both rapid vascular dilatation and longer-term effects on gene expression in vascular cells (reviewed in Mendelsohn and Karas 1 ). At physiologically relevant concentrations of estrogen, studies support that estrogen receptors (ERs) ␣ and ␤ mediate both the rapid and the long-term cardiovascular effects of estrogen. ER␣ and ER␤ are expressed in both vascular endothelial and smooth muscle cells, but their physiological roles in the vasculature are incompletely understood.
Using wild-type and estrogen receptor knockout mice, we have previously studied the role of ER␣ and ER␤ in mediating the vascular protective effects of estrogen in a mouse carotid artery injury model. 2, 3, 5, 6 Studies of mice harboring single gene deletions of either ER␣ or ER␤ showed that treatment of ovariectomized female mice with nanomolar concentrations of 17␤-estradiol (E 2 ) inhibits the response to vascular injury to equivalent levels in wild-type mice, ER␣KO Chapel Hill (ER␣KO CH ) and ER␤KO CH . 2, 5 These findings suggested that ER␣ and ER␤ are able to complement one another such that each receptor alone is sufficient to mediate the vascular protective effects of estrogen, or that the vascular protective effects of estrogen are mediated by an ER␣/ER␤independent pathway. To distinguish between these 2 hypotheses, studies of vascular injury in ER␣,␤KO CH (double) estrogen receptor knockout mice were performed. 6 However, the effect of estrogen on vascular injury in these mice was complex. Although E 2 no longer inhibited the increases in medial carotid area after injury in the ER␣,␤KO CH mice, E 2 still significantly inhibited vascular smooth muscle cell (VSMC) proliferation after injury. In addition, E 2 also caused a significant increase in uterine weight in the ER␣,␤KO CH mice. 6 These data showed that the role of estrogen receptors could diverge for specific components of the vascular injury response in the ER␣,␤KO CH mice. However, the results left unresolved what is responsible for estrogen inhibition of VSMC proliferation and the increase in uterine weight in the ER␣,␤KO CH mice. These could be due to an unidentified third estrogen receptor or to residual function of protein from an ER␣ splice variant known to be expressed in the parental ER␣KO CH mice. 7 To resolve the question as to how estrogen inhibits vascular injury in the mouse carotid injury model, we have studied the effects of estrogen on the response to vascular injury in the newly created ER␣KO Strasbourg (ER␣KO St ) mice.
Materials and Methods

Generation of ER␣KO Strasbourg Mice
Full details have been described recently. 8 In brief, to create mice fully null for ER␣, a targeting vector containing exon 3 of ER␣, a TKneo cassette, and a loxP site was generated using PCR-based site-directed mutagenesis, as described. 8 The targeting vector was electroporated into 129/SvPas H1 embryonic stem (ES) cells, and after expansion of G418 neomycin-resistant clones, ES cells containing a targeted ER␣ allele were identified and injected into C57BL/6 blastocysts. These were introduced into pseudopregnant hosts to obtain chimeric males that transmitted the mutation through crosses with C57BL/6 females, yielding heterozygous mice, which were next bred with homozygous CMV-Cre transgenic mice to generate heterozygous mice in which both ER␣ exon 3 and the selectable marker were deleted. Inbreeding of heterozygous ER␣ mice yielded mice homozygous for the deletion of ER␣ exon 3 (ER␣KO St mice), 8 in numbers consistent with Mendelian expectations. Institutional guidelines of the IACUC and DLAM were followed in the care and use of animals in this study.
Mouse Model of Carotid Arterial Injury
The mouse carotid injury model used in this study has been described and validated in detail. 2, 3, 5, 6 The general study design, as previously, begins with ovariectomies of 10-to 12-week-old female mice 7 to 10 days before the start of the experiment. At day Ϫ7, vehicle-or E 2 -releasing pellets (0.1 mg, 21-day release pellets, Innovative Research of America) were implanted in each animal. At Day 0, carotid injuries were performed, followed by implantation of osmotic minipumps calibrated to release BrdU over the course of the experiment (25 mg BrdU/kg per day), to allow measurement of the extent of vascular cell proliferation. Mice were killed at day 14.
Bloods were harvested and blood vessels were fixed at physiological pressures (100 to 120 mm Hg), followed by analyses for each of the endpoints described, as previously. 2, 3, 5, 6 
Morphometry and Immunohistochemistry
Parallel sections from all 92 carotids (46 injured, 46 contralateral uninjured) were stained as described previously with hematoxylineosin and elastin, and area measurements were made using a computerized morphometric analysis system on the elastin-stained sections. 3 BrdU-labeled cells were identified by immunostaining and were counted in all sections. Two independent observers fully blinded to treatment made all measurements. To distinguish between different vascular cell types, immunostaining also was performed on parallel carotid artery sections using endothelial cell-specific (factor VIII-related antigen) and VSMC-specific (␣-actin) antibodies. 3 BrdU-positive cells were categorized as endothelial cells if they were positive for factor VIII-related antigen and negative for ␣-actin, and as VSMCs if the converse pattern was seen. Proliferation Index is calculated as the ratio of BrdU-positive VSMCs to unstained medial nuclei in each section. 6 Proteoglycan deposition was quantified using Movat's pentachrome staining 9 and computerized quantification of positive (blue) regions ( Figure 2 ). For all statistical analyses, genotype and treatment groups were independent variables and thus analyzed using a 2-factor ANOVA, with post hoc pairwise comparisons made with the Student-Newman-Keuls test.
Results and Discussion
ER␣KO St mice and their wild-type (WT) littermates were used to study the effect of estrogen on the vascular response to injury. 2,3,5,6 Complete ablation of ER␣ in ER␣KO St mice was confirmed by the absence in their uteri of any ER␣ polypeptide immunoreactive with antibody directed against ER␣ C-terminus, as well as by the absence of mRNA for ER␣-containing transcripts of any exons located downstream of exon 2. 8 The mouse carotid injury model involves the uniform passage of a fine wire into the common carotid artery, causing endothelial denudation and an injury response characterized by increases in medial area and VSMC proliferation. 3, 10 The response to vascular injury was studied in 46 normocholesterolemic, ovariectomized adult female mice (21 ER␣KO St and 25 WT littermates) randomized to receive vehicle alone or 17␤-estradiol (E 2 ), as described. [2] [3] [4] [5] [6] No differences in the total or HDL cholesterol levels or triglycerides were noted between the experimental groups (Table) . Estrogen levels were undetectable in vehicle-treated mice. Estrogen-treated animals attained mean circulating estrogen levels of 90 to 117 pg/mL (0.33 to 0.43 nmol/L). Uterine weights were low in both vehicle-treated WT and ER␣KO St mice (Table and Figure 1 ). In WT mice, E 2 caused an increase in uterine weight from 9.4Ϯ0.5ϫ10 Ϫ3 to 110.5Ϯ7.2ϫ10 Ϫ3 g (PϽ0.001). In contrast, E 2 had no effect on ER␣KO St uterine weights ( Figure 1 intimal response was evident after the endothelial denudation injury. Only 2 of the 46 injured vessels examined demonstrated any significant formation of neointima, and 1 injured carotid artery demonstrated evidence of thrombosis in situ. Injury led to a significant increase in medial area of both WT and ER␣KO St carotid arteries (Figures 2a through 2c and 3A).
In the WT mice, the medial area per section increased from 18.2Ϯ0.8ϫ10 Ϫ3 to 27.9Ϯ2.8ϫ10 Ϫ3 mm 2 after injury (Pϭ0.001). As in previous studies, 2,3,5,6 estrogen replacement significantly inhibited the injury-induced increase in medial area in the WT mice to levels comparable to uninjured animals (to 20.8Ϯ1.3ϫ10 Ϫ3 mm 2 , PϽ0.001 versus Inj, ϪE 2 ; PϭNS versus Uninj) ( Figure 3A ). In ER␣KO St mice, significant injury was also noted, with the medial area per section increasing from 18.5Ϯ0.6ϫ10 Ϫ3 to 22.0Ϯ0.8ϫ10 Ϫ3 mm 2 after injury (PϽ0.05). However, estrogen replacement failed to inhibit this response in ER␣KO St mice (Inj, ϩE 2 ϭ22.6Ϯ1.2ϫ10 Ϫ3 mm 2 , PϭNS versus Inj, ϪE 2 ) ( Figure 3A) . The medial area thickening after injury in the vehicle-treated ER␣KO St mice was significantly less than that of the vehicle-treated, WT mice (Pϭ0.007) ( Figure 3A ). The increase in medial area that occurs in response to vascular injury is due to an increase in both cellular proliferation and deposition of matrix proteins elaborated by vascular wall cells. 11 We quantified the extent of deposition of proteoglycan, one of the principal matrix substances elaborated, in carotid sections from all mice in the study (Figures 2d through 2f and 3B) . In WT mice, the proteoglycan deposition per section rose from undetectable levels in uninjured vessels to 24.2Ϯ3.8% of total medial area after injury. Estrogen replacement significantly inhibited proteoglycan deposition in WT mice (to 7.6Ϯ1.9% of total area, PϽ0.001) ( Figure 3B ). In ER␣KO St mice, proteoglycan deposi-tion per section rose from undetectable levels in uninjured vessels to 16.3Ϯ2.8% of total medial area. Estrogen replacement failed to significantly inhibit this response in ER␣KO St mice (Inj, ϪE 2 ϭ16.3Ϯ2.8% versus Inj, ϩE 2 ϭ13.5Ϯ2.1% of total medial area, PϭNS; Figure 3B ). The proteoglycan deposition per section in vehicle-treated ER␣KO St mice was less than that in WT, vehicle-treated mice (Pϭ0.02).
The extent of endothelial cell and VSMC proliferation over the 14 days after injury was quantified by immunostaining for 5-Bromo-2Ј-deoxyuridine (BrdU) in sections from both injured arteries and the contralateral uninjured vessels ( Figures  2g through 2i and 4) . 5, 6 Injury induced significant increases in endothelial cell labeling in both WT and ER␣KO St mice, but the extent of endothelial cell labeling was not different for these groups, nor was it affected by estrogen treatment (cf. references 2, 3, 5, and 6). Medial VSMC cell proliferation was also quantified (Figure 4) . In uninjured vessels from WT mice, very few (mean, Ͻ1 cell/section) cells were labeled. Injury resulted in a marked increase in the proliferation of medial VSMCs in WT animals (mean Proliferation Index 6 (PI)ϭ2.8Ϯ0.8, PϽ0.01; Figure 4 ). E 2 inhibited this increase significantly in the WT mice (to PIϭ0.9Ϯ0.3, PϽ0.05; Figure 4 ), although not completely to the level of uninjured vessels. Medial VSMC labeling also was negligible in the uninjured vessels from ER␣KO St mice (Ͻ1 cell/section) and increased significantly after carotid artery injury (to 1.1Ϯ0.3, PϽ0.01; Figure 4) . In contrast to their WT littermates, VSMC proliferation was not inhibited significantly by estrogen treatment in ER␣KO St mice (meanϭ0.8Ϯ0.1, PϭNS; Figure  4 ). The extent of VSMC proliferation was less in injured blood vessels from vehicle-treated ER␣KO St mice than in those from WT, vehicle-treated mice (PIϭ1.1Ϯ0.3 versus 2.8Ϯ0.8, respectively, PϽ0.05; Figure 4 ). Thus, for all 3 measures of vascular injury response, the ovariectomized, vehicle-treated WT mice demonstrated greater injury responses than ER␣KO St mice, and the protective effects of estrogen observed in the WT mice were absent in ER␣KO St mice.
Numerous studies to date implicate estrogen receptors in the regulation of the vascular protective effects of estrogen, 1,3-10 but remain inconclusive as to the relative roles of ER␣, ER␤, and/or a potential third estrogen-responsive receptor in mediating this protection. ER␣KO CH , the first ER␣ knockout mice to be generated, were created by insertion of a neo gene into exon 2 of ER␣. 4 ER␣KO CH mice have marked reproductive phenotypes, 4,12 but also display a low level of residual, high-affinity estradiol binding, as well as expression of two ER␣-derived transcripts, one of which encodes a truncated ER␣ with intact DNA-and hormone-binding domains. In contrast, ER␣KO St mice are fully null. 7, 8 ER␣KO CH mice are protected against vascular injury equally well by physiological estrogen replacement as their WT littermates. 2 Mice generated with a disruption of ER␤ in both Chapel Hill (ER␤KO CH ) 5 and Strasbourg (ER␤KO St ) 8 both appear to be completely null for ER␤ and to have very similar reproductive phenotypes. 13, 8 ER␤KO CH mice also are protected against vascular injury equally well by physiological estrogen replacement as their WT littermates. 5 Finally, ER␣,␤KO CH mice, 6 generated by crossing ER␣KO CH and ER␤KO CH mice, retain some estrogen responses in both uterine and vascular tissues. 6 The present data show that ER␣ mediates the inhibitory effects of E 2 on all injury responses measured in the mouse carotid vascular injury model. This resolves a longstanding debate in the literature regarding whether ERs mediate the vascular protective effects of estrogen at all, and addresses the relative importance of ER␣ and ER␤ in these effects. ER␣ and ER␤ are transcription factors that alter gene expression in both reproductive and nonreproductive target tissues, including liver, bone, brain, and the cardiovascular system. 1,14 -16 The present findings highlight the potential importance of ER␣ and ER␣regulated genes in the protective effects of estrogen against vascular injury. Some likely ER␣-regulated gene candidates include estrogen-induced genes, such as endothelial NOS, 17 cyclooxygenase-1, 18 and matrix metalloproteinase-2, 19 and estrogen-inhibited genes such as endothelin-1, 20,21 vascular adhesion molecules, 22 and the angiotensin II receptor AT 1 23 (see also summary Tables in references 1, 24, 25 ). The loss of estrogen protection in the ER␣KO St mice thus may be due in part to the altered expression of ER␣-regulated genes responsible for estrogen-mediated enhancement of endothelial cell proliferation.
Based on the present study and very recent work from several laboratories, a molecular explanation is now possible for the results reported here and previously. 2, 6 The Korach laboratory 7 originally reported that their ER␣KO CH mice still encodes a variant ER␣ transcript, corresponding to a partial deletion in the A/B domain of 64 amino acids and an insertion of 7 amino acids encoded by the neomycin insert. In heterologous expression studies, they showed that this transcript, which would encode a truncated, 55-kDa ER (ER␣55), retained estrogen-dependent transcriptional activity, although protein expression was not evaluated in the murine tissues. Recently, Flouriot and colleagues 26 characterized a new 46-kDa endogenous isoform of ER␣ in nonvascular cells. This isoform, encoded by an ER␣ transcript lacking the first coding exon, is missing the N-terminal 173 amino acids of full-length ER␣, but retains transcriptional activity in the appropriate cell type. A separate study published while this article was under review and including those authors of this work responsible for construction of the ER␣KO St mice (A.K., P.C.), 27 confirmed the presence of ER␣ mRNA variants in ER␣KO CH mice. In the aorta of ovariectomized wild-type mice, full-length ER␣ transcript and another 540-bp PCR product were detected, the latter resulting from splicing of exon 1 such that it would encode an ER␣46 isoform deleted for the A/B domain, as reported previously by the Gannon laboratory. 26 No RT-PCR products were generated from mRNA obtained in the aorta of the ER␣KO St mutant mice in this study, but 3 unique RT-PCR products were detected in the aorta of ER␣KO CH mice. 27 Sequencing revealed that 1 was identical to the 540-bp splice variant found in wild-type mice and 2 were those reported previously by Couse et al, 7 including 1 predicted to encode chimeric ER␣55. These investigators go on to show expression of a 55-kDa protein in both uterus and aorta of ER␣KO CH mice using a C-terminal ER␣ antibody. 27 Taken together, the available data now support that the ER␣KO CH mice express a truncated isoform of ER␣ in the vasculature that can mediate several physiological functions. The isoform expressed in ER␣KO CH mice, which lacks the AF-1 of ER␣, is sufficient to mediate the effect of E 2 on the uterine response (present study and Pendaries et al 27 ) , the endothelial production of NO, 27 and the inhibition of smooth muscle proliferation, but not the carotid medial thickening in response to injury. 2, 6 It may therefore be useful to reexamine at least some prior studies in which ER␣KO CH mice were used to study estrogen action in target tissues. 28 Data now exist to support that ER␣ mediates 3 effects of estrogen in the vessel wall, including acceleration of reendothelialization, 29 alteration of endothelial NO production, 27 and inhibition of the vascular injury response reported here. It is important to note that there is also a recently identified role for ER␤ in vascular physiology and the control of blood pressure. ER␤KO mice demonstrate widespread vascular abnormalities and develop hypertension as they age. 30 Thus, both ER␣ and ER␤ mediate physiologically important effects in the vasculature.
Wild-type mice uniformly displayed the largest vascular injury response for all parameters measured in the studies reported here. These animals, unlike the other groups, have an unliganded ER␣, which is known to be activated by estrogenindependent pathways that can lead to changes in the expression of a different set of genes than those recruited by estrogen-bound ER␣. [31] [32] [33] This raises the possibility that ligand-independent activation of ER␣ contributes to the pronounced vascular injury response observed in vehicletreated WT mice. This might be relevant to the recognized increase in ischemic cardiovascular diseases that occurs in postmenopausal women, 34 -36 in whom there is an analogous unliganded estrogen receptor. In summary, the present study shows that ER␣ mediates the inhibition of the vascular injury response by estrogen. These data help resolve the longstanding debate regarding the role of estrogen receptors, and the relative roles of ER␣ and ER␤, in the protective effects of estrogen against the vascular injury response. They also suggest that identification of novel vascular cell-specific ER␣ agonists may prove to be useful therapeutic agents in cardiovascular diseases.
